BIOSPAIN 2018 consolidates the congress as the 5th world biotechnology event

Paula Cañal
Oct 11, 2018


The Spanish Association of Biocompanies (ASEBIO) and the Regional Government of Andalusia have concluded the 9th edition of the International Meeting on Biotechnology BIOSPAIN 2018, which has broken attendance records and is crowned as the fifth world event on biotechnology.

During the inauguration of the congress, Ion Arocena, director of ASEBIO, wanted to highlight the improvement in attendance compared to the previous edition thanks to "a programme aligned with the industry's priorities". One of the main indicators of this success has been the number of meetings arranged by means of the partnering system used during the congress, with which about 4,500 meetings between attendees were calculated.

The Biotechnology Business Institute's team travelled to Seville to participate in the new edition of BIOSPAIN, an event to which it is assiduous. The directors of the center, Juan Garcia and Natalia Oñate, took the opportunity to publicize the activity of the center, networking and strength alliances with the Spanish and international biotech community.

The aim of this ninth edition has been "to enhance the value of the Spanish biotechnology ecosystem to investors and market players both nationally and internationally," explained the director of ASEBIO during the presentation of the event in Seville. In this sense, the congress brought together more than 600 companies from 30 countries, more than 200 exhibitors and almost 50 investors of great European relevance in Life Sciences. 

The main attendance that has highlighted in this edition has been the presence of the Top Ten of investment funds, that manage more than 8,000 million euros of assets in life sciences. Key players in the development of national biotechnology such as Ysios Capital Partners, Fund+, Johnson & Johnson Innovation, Kreos Capital Partners, Forbion Capital, Kreos Capital, Medicxi and M Ventures are some of the investors who attended the congress. 

To this participation is added the interest of the big names in the sector. For the first time, the major pharmaceutical companies took part in BIOSPAIN, including Johnson & Johnson, Lilly, MSD and Novartis. Big Pharma presented their development strategies in search of new alliances with biotech start-ups. "We have managed to turn it into the main platform for boosting international financing and business collaborations at the service of the Spanish biotech industry", added Arocena.

Once again, the biomedical area, agroalimentary and industrial biotechnology and access to financing were the central axis of the meeting. Other current topics, such as advanced therapies, biobanks, circular economy, artificial intelligence, genetic editing, immunotherapy, precision medicine and antibiotic resistance have been other subjects of interest throughout the congress.

 

Latest news

BIOSPAIN 2018 consolidates the congress as the 5th world biotechnology event

The ninth edition of the BIOSPAIN International Biotechnology Meeting, which ASEBIO organizes every two years, brought together more than 600 companies from 30 countries in the city of Seville.

The Summer Charity Cocktail supports companies researching in pediatric cancer, under the first Childhood Cancer Innovation Award

The charity event, organized by the Biotechnology Business Institute in collaboration with the Richi Childhood Cancer Foundation, raised money from the attendees to boost innovative companies researching in pediatric oncology.

El IEB firma acuerdos de colaboración con el IRB y la Fundació Bosch i Gimpera para su nueva actividad, Discover and Transfer

El IRB Barcelona y la Fundació Bosch i Gimpera se suman a los programas formativos de máster y posgrado del Instituto Empresarial de Biotecnología con la firma de convenios de colaboración en el marco de la actividad Discover and Transfer. Esta alianza permite a los estudiantes del actual año académico el seguimiento de 4 patentes – dos de cada centro – de forma paralela a las clases teóricas.

The Biotechnology Business Institute finishes a new master’s edition under the first year of the Discover & Transfer educational agreement

Last week we concluded the master’s edition 2017-2018. After nine months of hard work, board of professors, students and managing directors of the Biotechnology Business Institute joined together the presentation of the final projects in the framework of the first year of the educational agreement Discover & Transfer.

Filter by category